H. Zeng

发表

A pilot study of stereotactic body radiotherapy combined with pelvic radiotherapy and GTVp boost based on multiparameter magnetic resonance image in patients with high-risk prostate cancer

Fang Wang, Junru Chen, Jin Yao, 2023, Medicine.

G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications

Mingchen Shi, H. Zeng, Yuzhuo Wang, 2024, Cancers.

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Junru Chen, Haoyang Liu, Sha Zhu, 2024, Cancer Treatment Reviews.

Molecular complexity of intraductal carcinoma of the prostate

Sha Zhu, Nan Xu, H. Zeng, 2024, Cancer medicine.

Low anterior resection syndrome and quality of life after intersphincteric resection for rectal cancer: a propensity score-matched study

H. Zeng, Y. Shen, T. Yang, 2023, Techniques in Coloproctology.

The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis

Junru Chen, Haoyang Liu, Jinge Zhao, 2024, BMC cancer.

AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration‐resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first‐line therapy

Jiyan Liu, H. Zeng, L. Nie, 2019, The Prostate.

The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study

Xingming Zhang, P. Shen, Zhenhua Liu, 2024, World journal of urology.

Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinoma

Junru Chen, Jinge Zhao, Xingming Zhang, 2024, European journal of medical research.